<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091974</url>
  </required_header>
  <id_info>
    <org_study_id>UCCS07090</org_study_id>
    <secondary_id>1R01CA126968-01A1</secondary_id>
    <nct_id>NCT01091974</nct_id>
  </id_info>
  <brief_title>Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy</brief_title>
  <official_title>Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a four-arm, randomized, controlled, clinical trial examining the efficacy of of
      cognitive behavioral therapy (CBT)-I and armodafinil in reducing insomnia in 226 female
      breast cancer patients who report sleep disturbances following completion of chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment Protocol: CBT-I and armodafinil are being studied in a four-arm, randomized,
      controlled, clinical trial of 226 cancer survivors with chronic insomnia who are at least one
      month post treatment. The seven-week intervention is designed to determine the efficacy and
      acceptability of these treatment strategies in reducing insomnia in cancer survivors.
      Assessments will be made by questionnaires before, during, and two weeks following the study
      intervention. All ancillary treatments, as appropriate for control of symptoms caused by the
      cancer or its treatment may be administered as clinically indicated.

      Withdrawal of Sleep Medications: All participants, prior to beginning the baseline data
      collection phase of the study, must have withdrawn from all sleep medications, including:
      prescription, over-the-counter, CAM and herbal remedies for at least one week prior to
      beginning the study.

      CBT-I (Arms 3 &amp; 4): CBT-I will be provided on an individual basis to all patients in study
      Arms 3 &amp; 4 by a licensed clinical psychologist trained in CBT-I by Dr. Perlis. Subjects in
      these two study arms will receive 7 weeks of CBT-I, using a structured research grade
      protocol developed at the UR-SNRL. This manualized intervention, which exists as a published
      text: Perlis et al., 2005, includes four essential components: Sleep Restriction Therapy,
      Stimulus Control Instruction, Sleep Hygiene Guidelines, and a session of cognitive therapy.

      Data Collection: Patients will complete the Insomnia Severity (ISI) at the time of consent
      and every Friday during weeks 3-11 of the study. A follow-up call by study personnel will be
      made to each participant not currently receiving CBT-I on each of these Fridays to promote
      compliance, prompt completion, assess potential side effects of study medication, and answer
      patient questions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insomnia Severity Index From Baseline to Post-intervention</measure>
    <time_frame>ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre).</time_frame>
    <description>The Insomnia Severity Index (ISI) is a commonly used, 7-item psychometrically validated measure used to rate insomnia with 0-7 = absence of insomnia, 8-14 = subthreshold insomnia symptoms, 15-21 = moderate insomnia, and 22-28 = severe insomnia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue Will be Assessed by the Total Score of the Revised Brief Fatigue Inventory (BFI) .</measure>
    <time_frame>ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre).</time_frame>
    <description>The revised Brief Fatigue Inventory (BFI) is a 9-item, patient-report instrument with established reliability and validity. The BFI allows for the rapid assessment of fatigue level in cancer patients and identifies those patients with severe fatigue. Three items ask patients to rate their fatigue &quot;now,&quot; and fatigue at its &quot;worst&quot; and &quot;usual&quot; for the last 24 hours. The 11-point scales are bounded by 0 = &quot;no fatigue&quot; and 10 = &quot;fatigue as bad as you can imagine.&quot; Using the same type of scales, the remaining questions ask patients to rate how their fatigue interferes with several functional domains, including general activity, walking, mood, work, and relations with others. These scales are bounded by 0 = &quot;does not interfere&quot; and 10 = &quot;interferes completely.&quot; A global fatigue score (ranging from 0-10) can be obtained by averaging all the items on the BFI.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Insomnia</condition>
  <condition>Fatigue</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1 - CBT-I + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBT-I and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - CBT-I + Armodafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBT-I + Armodafinil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 - Placebo only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 - Armodafinil only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Armodafinil only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>armodafinil</intervention_name>
    <description>Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)</description>
    <arm_group_label>2 - CBT-I + Armodafinil</arm_group_label>
    <arm_group_label>4 - Armodafinil only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo for 47 days</description>
    <arm_group_label>1 - CBT-I + placebo</arm_group_label>
    <arm_group_label>3 - Placebo only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT-I</intervention_name>
    <description>Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)</description>
    <arm_group_label>1 - CBT-I + placebo</arm_group_label>
    <arm_group_label>2 - CBT-I + Armodafinil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a diagnosis of cancer.

          2. Be able to understand written and spoken English

          3. Be able to swallow medication

          4. Have preferred sleep phase between 7:30 pm and 11:00 am

          5. Be willing to discontinue any medications/OTCs/Herbals for sleep for the 11-week study
             period

          6. Be presumed to be in a state of cancer remission; use of tamoxifen, an aromatase
             inhibitor, and/or Herceptin is permitted

          7. Self-report problems with insomnia for at least three months and that the insomnia
             began or got worse with the onset of cancer or treatment

          8. Have completed chemotherapy and or radiation not less than one month ago. Note: Both
             types of treatment must be completed at least one month ago if patient receives
             chemotherapy and radiation therapy and there is no outer limit to how long ago
             treatments were completed.)

          9. Report insomnia on the SDS-CL at a frequency of at least 3 days a week

        Exclusion Criteria:

          1. Have ever taken modafinil or had CBT-I therapy. CBT-I therapy for the sake of this
             protocol will be defined as any cognitive behavioral-based treatment for insomnia that
             includes a sleep restriction component.

          2. Have an unstable medical or psychiatric illness (Axis I-current or within the last 5
             years)

          3. Have a history of seizures or severe headaches, or uncontrolled cardiac disease or
             hypertension

          4. Be presently taking an anticoagulant or a corticosteroid

          5. Have taken amphetamines (e.g., methylphenidate, pemoline [Cylert®] or similar psycho
             stimulants) within the past 30 days

          6. Be currently pregnant or nursing

          7. Have a history of substance abuse, or meet criteria for current alcohol abuse or
             dependence as assessed by a CAGE test score &gt;=2 or an Alcohol Use Disorders
             Identification Test (AUDIT) score &gt;=13

          8. Have surgery planned within the study period

          9. Have have ever been diagnosed with sleep apnea or have sleep apnea as indicated by
             endorsing either question 11 (I wake up choking or gasping for air) or question 12 (My
             bed partner has noticed that I seem to stop breathing) on the Sleep Disorders Symptom
             Check at the &quot;Often&quot; or &quot;Frequently&quot; level.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Roscoe, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester James P. Wilmot Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <results_first_submitted>February 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 13, 2015</results_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Joseph Roscoe</investigator_full_name>
    <investigator_title>Research Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Insomnia</keyword>
  <keyword>Fatigue</keyword>
  <keyword>QOL</keyword>
  <keyword>CBT</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Survivors</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>138 Patients were consented of which 114 were eligible.</recruitment_details>
      <pre_assignment_details>18 Withdrew prior to randomization (3 ceased responding to contacts, 4 changed mind , 3 began or restarted sleep medication, 4 did not complete baseline measures, 1 did not receive approval from physician to participate, 1 found the diaries too much trouble, 1 did not want to take study medication, and 1 had a family emergency).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1 - (CBT-I) + Placebo</title>
          <description>Placebo Comparator: Placebo for 47 days
CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)</description>
        </group>
        <group group_id="P2">
          <title>2 - CBT-I + Armodafinil</title>
          <description>Armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)</description>
        </group>
        <group group_id="P3">
          <title>3- Placebo Only</title>
          <description>Placebo Comparator: Placebo for 47 days</description>
        </group>
        <group group_id="P4">
          <title>4 - Armodafinil Only</title>
          <description>Armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not start intervention</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>resumed sleep medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>side-effects</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 - CBT-I + Placebo</title>
          <description>CBT-I and placebo
Placebo Comparator: Placebo for 47 days
CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)</description>
        </group>
        <group group_id="B2">
          <title>2 - CBT-I + Armodafinil</title>
          <description>CBT-I + Armodafinil
armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)</description>
        </group>
        <group group_id="B3">
          <title>3 - Placebo Only</title>
          <description>Placebo only
Placebo Comparator: Placebo for 47 days</description>
        </group>
        <group group_id="B4">
          <title>4 - Armodafinil Only</title>
          <description>Armodafinil only
armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="9.9"/>
                    <measurement group_id="B2" value="56" spread="10.2"/>
                    <measurement group_id="B3" value="52" spread="11.5"/>
                    <measurement group_id="B4" value="57" spread="7.4"/>
                    <measurement group_id="B5" value="56.1" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Insomnia Severity Index From Baseline to Post-intervention</title>
        <description>The Insomnia Severity Index (ISI) is a commonly used, 7-item psychometrically validated measure used to rate insomnia with 0-7 = absence of insomnia, 8-14 = subthreshold insomnia symptoms, 15-21 = moderate insomnia, and 22-28 = severe insomnia.</description>
        <time_frame>ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - (CBT-I) + Placebo</title>
            <description>Placebo Comparator: Placebo for 47 days
CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)</description>
          </group>
          <group group_id="O2">
            <title>2 - CBT-I + Armodafinil</title>
            <description>Armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)</description>
          </group>
          <group group_id="O3">
            <title>3- Placebo Only</title>
            <description>Placebo Comparator: Placebo for 47 days</description>
          </group>
          <group group_id="O4">
            <title>4 - Armodafinil Only</title>
            <description>Armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insomnia Severity Index From Baseline to Post-intervention</title>
          <description>The Insomnia Severity Index (ISI) is a commonly used, 7-item psychometrically validated measure used to rate insomnia with 0-7 = absence of insomnia, 8-14 = subthreshold insomnia symptoms, 15-21 = moderate insomnia, and 22-28 = severe insomnia.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.93" spread="1.85"/>
                    <measurement group_id="O2" value="-6.36" spread="1.84"/>
                    <measurement group_id="O3" value="1.04" spread="1.89"/>
                    <measurement group_id="O4" value="-1.43" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue Will be Assessed by the Total Score of the Revised Brief Fatigue Inventory (BFI) .</title>
        <description>The revised Brief Fatigue Inventory (BFI) is a 9-item, patient-report instrument with established reliability and validity. The BFI allows for the rapid assessment of fatigue level in cancer patients and identifies those patients with severe fatigue. Three items ask patients to rate their fatigue “now,” and fatigue at its “worst” and “usual” for the last 24 hours. The 11-point scales are bounded by 0 = “no fatigue” and 10 = “fatigue as bad as you can imagine.” Using the same type of scales, the remaining questions ask patients to rate how their fatigue interferes with several functional domains, including general activity, walking, mood, work, and relations with others. These scales are bounded by 0 = “does not interfere” and 10 = “interferes completely.” A global fatigue score (ranging from 0-10) can be obtained by averaging all the items on the BFI.</description>
        <time_frame>ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre).</time_frame>
        <population>Note: One patient randomized to the placebo only condition failed to provide data and was not included in the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - (CBT-I) + Placebo</title>
            <description>Placebo Comparator: Placebo for 47 days
CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)</description>
          </group>
          <group group_id="O2">
            <title>2 - CBT-I + Armodafinil</title>
            <description>Armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)</description>
          </group>
          <group group_id="O3">
            <title>3- Placebo Only</title>
            <description>Placebo Comparator: Placebo for 47 days</description>
          </group>
          <group group_id="O4">
            <title>4 - Armodafinil Only</title>
            <description>Armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue Will be Assessed by the Total Score of the Revised Brief Fatigue Inventory (BFI) .</title>
          <description>The revised Brief Fatigue Inventory (BFI) is a 9-item, patient-report instrument with established reliability and validity. The BFI allows for the rapid assessment of fatigue level in cancer patients and identifies those patients with severe fatigue. Three items ask patients to rate their fatigue “now,” and fatigue at its “worst” and “usual” for the last 24 hours. The 11-point scales are bounded by 0 = “no fatigue” and 10 = “fatigue as bad as you can imagine.” Using the same type of scales, the remaining questions ask patients to rate how their fatigue interferes with several functional domains, including general activity, walking, mood, work, and relations with others. These scales are bounded by 0 = “does not interfere” and 10 = “interferes completely.” A global fatigue score (ranging from 0-10) can be obtained by averaging all the items on the BFI.</description>
          <population>Note: One patient randomized to the placebo only condition failed to provide data and was not included in the analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.041" spread="0.411"/>
                    <measurement group_id="O2" value="1.209" spread="0.364"/>
                    <measurement group_id="O3" value="2.971" spread="0.534"/>
                    <measurement group_id="O4" value="3.167" spread="0.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed throughout the study duration, for up to 24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1 - (CBT-I) + Placebo</title>
          <description>Placebo Comparator: Placebo for 47 days
CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)</description>
        </group>
        <group group_id="E2">
          <title>2 - CBT-I + Armodafinil</title>
          <description>Armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)</description>
        </group>
        <group group_id="E3">
          <title>3- Placebo Only</title>
          <description>Placebo Comparator: Placebo for 47 days</description>
        </group>
        <group group_id="E4">
          <title>4 - Armodafinil Only</title>
          <description>Armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness/tingling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph A. Roscoe Ph.D.</name_or_title>
      <organization>University of Rochester Medical Center</organization>
      <phone>(585) 275-9962</phone>
      <email>Joseph_Roscoe@URMC.Rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

